Want to see PMVP full AI Analyst Report?
PMV Pharmaceuticals (PMVP) Stock Statistics & Valuation Metrics
Total Valuation
PMV Pharmaceuticals has a market cap or net worth of $98.92M. The enterprise value is -$7.68M.
- Market Cap
- $98.92M
- Enterprise Value
- -$7.68M
Share Statistics
PMV Pharmaceuticals has 75,513,060 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 75,513,060
- Owned by Insiders
- 2.38%
- Owned by Institutions
- 10.37%
Financial Efficiency
PMV Pharmaceuticals’s return on equity (ROE) is -0.74 and return on invested capital (ROIC) is -79.45%.
- Return on Equity (ROE)
- -0.74
- Return on Assets (ROA)
- -0.67
- Return on Invested Capital (ROIC)
- -79.45%
- Return on Capital Employed (ROCE)
- -0.82
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.44M
- Employee Count
- 54
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of PMV Pharmaceuticals is -0.92. PMV Pharmaceuticals’s PEG ratio is -0.09.
- PE Ratio
- -0.92
- PS Ratio
- 0.00
- PB Ratio
- 0.98
- Price to FCF
- -0.98
- Price to Operating Cash Flow
- -0.98
- PEG Ratio
- -0.09
Income Statement
In the last 12 months, PMV Pharmaceuticals had revenue of 0 and earned -77.74M in profits. Earnings per share was -1.48.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -86.21M
- Pretax Income
- -79.91M
- Net Income
- -77.74M
- EBITDA
- -79.78M
- Earnings Per Share (EPS)
- -1.48
Cash Flow
In the last 12 months, operating cash flow was -71.27M and capital expenditures -14,000, giving a free cash flow of -71.28M billion.
- Operating Cash Flow
- -71.27M
- Free Cash Flow
- -71.28M
- Free Cash Flow per Share
- -1.34
Dividends & Yields
PMV Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -102.02%
- Earnings Yield
- -107.55%
Stock Price Statistics
- Beta
- 0.32
- 52-Week Price Change
- -6.43%
- 50-Day Moving Average
- 1.38
- 200-Day Moving Average
- 1.30
- Relative Strength Index (RSI)
- 47.42
- Average Volume (3m)
- 686.47K
Important Dates
PMV Pharmaceuticals upcoming earnings date is Nov 05, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
PMV Pharmaceuticals as a current ratio of 10.09, with Debt / Equity ratio of 0.80%
- Current Ratio
- 10.09
- Quick Ratio
- 10.09
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.47
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, PMV Pharmaceuticals has paid -2.17M in taxes.
- Income Tax
- -2.17M
- Effective Tax Rate
- 0.03
Enterprise Valuation
PMV Pharmaceuticals EV to EBITDA ratio is -0.76, with an EV/FCF ratio of -0.81.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.76
- EV to Free Cash Flow
- -0.81
- EV to Operating Cash Flow
- -0.81
Balance Sheet
PMV Pharmaceuticals has $79.43M in cash and marketable securities with $217.00K in debt, giving a net cash position of $79.21M billion.
- Cash & Marketable Securities
- $79.43M
- Total Debt
- $217.00K
- Net Cash
- $79.21M
- Net Cash Per Share
- $1.05
- Tangible Book Value Per Share
- $1.34
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for PMV Pharmaceuticals is $4.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $4.20
- Price Target Upside
- 220.61% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 9.38%
Scores
- Smart Score
- 7
- AI Score
- 48
